In support of improving patient care, The Robert Larner College of Medicine at The University of Vermont is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Vermont designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This program has been reviewed and is acceptable for up to 6.5 Nursing Contact Hours.
This course has been approved for 6.5 hours of pharmacy continuing education credit. The approval number issued is: UAN JA0000335-0000-26-024-L99-P.
The Robert Larner College of Medicine at the University of Vermont has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
This program is approved by the University of Vermont Doctor of Physical Therapy Program, a State of Vermont Office of Professional Regulation Approved Provider, for 6.5 CCUs for Physical Therapists in the State of Vermont.
This activity was planned by and for the healthcare team, and learners will receive 6.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Meeting Disclaimer: Regarding written materials and information received, written or otherwise, during this Conference, the scientific views, statements, and recommendations expressed during this activity represent those of the authors and speakers and do not necessarily represent the views of the University of Vermont.
Relevant Financial Relationships*
All those with control of content (speakers, planners, moderators, reviewers, staff) who have relevant financial relationships with “ineligible companies” are listed below. (An “ineligible company” is defined as those whose primary business is producing, marketing, selling, reselling or distributing healthcare products used by or on patients.)
The following have disclosed a relevant financial relationship with an ineligible company(s). These relationships have been mitigated:
Kimberley Sampson Paine, MD: Zealand -Advisory Board; Novo Nordisk -Advistory Board; Boehringer Ingelheim -Advisory Board
All others in control of content/CMIE reviewers do not have any relevant financial relationships with ineligible companies.
Support received from Ineligible Companies: None
*Having a financial relationship with an ineligible company, or discussing an unlabeled use of an ineligible product, may not prevent a speaker from making a presentation. However, the existence of the relationship must be made known to the planning committee prior to the conference, so that any relevant financial interest may be mitigated prior to the talk.
